Blueprint Medicines Corp

1BPMC

Company Profile

  • Business description

    Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

  • Contact

    45 Sidney Street
    CambridgeMA02139
    USA

    T: +1 617 374-7580

    E: [email protected]

    https://www.blueprintmedicines.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    649

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,365.7024.700.30%
CAC 407,593.8738.000.50%
DAX 4022,496.9871.150.32%
Dow JONES (US)40,939.80270.440.66%
FTSE 1008,496.801.950.02%
HKSE22,119.41111.300.51%
NASDAQ17,842.76396.422.27%
Nikkei 22536,452.30406.921.13%
NZX 50 Index12,148.60245.292.06%
S&P 5005,640.4071.341.28%
S&P/ASX 2008,145.6019.400.24%
SSE Composite Index3,279.037.62-0.23%

Market Movers